Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Bioasis and Chiesi announce licensing agreement

Bioasis Technologies and Chiesi Global Rare Diseases have entered into a worldwide, exclusive licensing agreement re the Bioasis platform technology, with a focus on four...

| By Kelley Gipson

Alexion reports progress re ULTOMIRIS®

Alexion Pharmaceuticals reports that the European Commission has approved ULTOMIRIS® (ravulizumab) — for certain adults and children with atypical hemolytic uremic syndrome (aHUS) … more Separately, Alexion...

| By Kelley Gipson

BioCT welcomes Erika Smith to Board

BioCT is pleased to welcome Erika Smith to the Board of Directors. Erika is the CEO of ReNetX Bio, a clinical stage, venture funded company in...

| By Kelley Gipson

NCI renews JAX cancer center designation

The Jackson Laboratory (JAX) reports that the National Cancer Institute has renewed JAX’s prestigious Cancer Center Support Grant for the 34th year. As one of...

| By Kelley Gipson

Tangen wins contract re candida auris

Tangen Biosciences has been awarded a contract to develop a point-of-care device for detection of Candida auris, a “superbug” that is resistant to anti-fungal drugs and...

| By Kelley Gipson

UConn advances research re liver and COVID-19

University of Connecticut researcher Dr. George Wu recently published a paper outlining his successful experiment delivering mitochondria to liver cells. This marks the first time researchers...

| By Kelley Gipson

SpringWorks advances re myeloma, solid tumors

SpringWorks Therapeutics reports that the first patient has been dosed in a Phase 1b clinical trial evaluating the company’s investigational gamma secretase inhibitor, nirogacestat, in combination with...

| By Kelley Gipson

Guilford, Branford biotechs fight COVID-19

Federal regulators have green-lighted Guilford’s AI Therapeutics to begin a clinical trial to test if its experimental drug for non-Hodgkin lymphoma and ALS could also...